Senator John Boozman (Republican-Arkansas) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on September 11th, the Senator disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 20th.
Senator John Boozman also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of iShares Core S&P 500 ETF (NYSEARCA:IVV) on 8/27/2026.
- Purchased $1,001 – $15,000 in shares of Otis Worldwide (NYSE:OTIS) on 8/27/2026.
- Purchased $1,001 – $15,000 in shares of State Street SPDR Portfolio S&P 500 ETF (NYSEARCA:SPYM) on 8/20/2026.
- Purchased $1,001 – $15,000 in shares of iShares Core S&P Small-Cap ETF (NYSEARCA:IJR) on 8/19/2026.
- Purchased $1,001 – $15,000 in shares of Avantis U.S. Small Cap Value ETF (NYSEARCA:AVUV) on 8/19/2026.
- Purchased $1,001 – $15,000 in shares of First Solar (NASDAQ:FSLR) on 8/13/2026.
- Sold $1,001 – $15,000 in shares of Constellation Energy (NASDAQ:CEG) on 8/13/2026.
- Sold $1,001 – $15,000 in shares of Cboe Global Markets (BATS:CBOE) on 7/31/2026.
- Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 7/30/2026.
- Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 7/23/2026.
Johnson & Johnson Stock Up 0.1%
Johnson & Johnson stock opened at $265.91 on Monday. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The stock has a fifty day simple moving average of $263.03 and a two-hundred day simple moving average of $245.93. The firm has a market cap of $640.82 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 2.54 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.
Insider Activity
In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. The trade was a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 87,569 shares of company stock valued at $23,064,544 over the last three months. 0.16% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in JNJ. California State Teachers Retirement System lifted its position in shares of Johnson & Johnson by 25,103.8% during the second quarter. California State Teachers Retirement System now owns 943,488,645 shares of the company’s stock worth $239,617,811,000 after purchasing an additional 939,745,213 shares in the last quarter. Auto Owners Insurance Co grew its stake in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Norges Bank purchased a new stake in Johnson & Johnson during the 4th quarter worth about $6,924,523,000. Capital World Investors acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $2,005,942,000. Finally, Jupiter Topco LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Analyst Ratings Changes
JNJ has been the topic of a number of recent analyst reports. Guggenheim raised their price target on Johnson & Johnson from $270.00 to $287.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a report on Wednesday, July 15th. Morgan Stanley increased their price target on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. Finally, Wells Fargo & Company raised their price target on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $274.13.
Get Our Latest Research Report on Johnson & Johnson
Johnson & Johnson News Roundup
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
- Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
- Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
- Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
- Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?
About Senator Boozman
John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry
Johnson & Johnson Company Profile
Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.
Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
